Targeted Protein Degraders Article Overview Introduction Evolution of ADCs Mechanism of Action Strategies for enhanced Efficacy & Safety Target Antigen Targeting Moiety IgG subtypes Small Format Drug Conjugates Linker Chemistry & Synthesis Conjugation Technologies Novel Payload Strategies Novel ADCs Immunostimulatory Antibody Conjugates (ISACs) Degrader Antibody Conjugates (DACs) Dual-drug ADCs Toxicity concerns & Mechanisms Clinical Aspects of ADCs Approved ADCs Combination Trials ADCs in Clinical Development ADCs for non-oncological applications Discontinued ADC Programs Business Aspects of ADCs Licensing, Mergers and Acquisitions Deals Venture Capital Events & IPOs Latest News NJ Bio, Inc. and Ajinomoto Bio-Pharma Services Partner to Advance ADC and AOC Development When Chemistry Became the Difference: Our Path from R&D to GMP Manufacturing NJ Bio to Present in Asia at Two Major Conferences in 2026 Resources Compliance & Accreditations
